Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 16
1995 60
1996 77
1997 63
1998 72
1999 64
2000 75
2001 84
2002 84
2003 96
2004 96
2005 135
2006 184
2007 141
2008 162
2009 174
2010 162
2011 147
2012 131
2013 128
2014 139
2015 114
2016 129
2017 109
2018 97
2019 82
2020 75
2021 78
2022 65
2023 43
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

2,812 results

Results by year

Filters applied: . Clear all
Page 1
Persistent pulmonary hypertension of the newborn.
Mandell E, Kinsella JP, Abman SH. Mandell E, et al. Pediatr Pulmonol. 2021 Mar;56(3):661-669. doi: 10.1002/ppul.25073. Pediatr Pulmonol. 2021. PMID: 32930508 Review.
Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension.
Wu S, Hoang HB, Yang JZ, Papamatheakis DG, Poch DS, Alotaibi M, Lombardi S, Rodriguez C, Kim NH, Fernandes TM. Wu S, et al. Chest. 2022 Dec;162(6):1360-1372. doi: 10.1016/j.chest.2022.06.042. Epub 2022 Jul 14. Chest. 2022. PMID: 35841932 Free PMC article. Review.
Among the targets in the NO pathway (sildenafil, tadalafil, and riociguat), important interactions with nitrates, protease inhibitors, and other phosphodiesterase inhibitors can cause profound hypotension. In the endothelin pathway, bosentan is associated with more drug in …
Among the targets in the NO pathway (sildenafil, tadalafil, and riociguat), important interactions with nitrates, protease inhibitors, and o …
Bosentan.
Cheng JW. Cheng JW. Heart Dis. 2003 Mar-Apr;5(2):161-9. doi: 10.1097/01.hdx.0000061696.83820.51. Heart Dis. 2003. PMID: 12713683 Review.
In patients with World Health Organization Class III and IV PAH, bosentan has demonstrated improvement in dyspnea and exercise tolerance. ...In addition, bosentan is not only a substrate but also an inducer of CYP3A4 and CYP2C9. ...
In patients with World Health Organization Class III and IV PAH, bosentan has demonstrated improvement in dyspnea and exercise tolera …
Morphea in Childhood: An Update.
Aranegui B, Jiménez-Reyes J. Aranegui B, et al. Actas Dermosifiliogr (Engl Ed). 2018 May;109(4):312-322. doi: 10.1016/j.ad.2017.06.021. Epub 2017 Dec 14. Actas Dermosifiliogr (Engl Ed). 2018. PMID: 29248149 Review. English, Spanish.
Childhood morphea is treated with phototherapy, oral or topical calcitriol, topical tacrolimus 0.1%, methotrexate, topical or systemic corticosteroids, mycophenolate mofetil, bosentan, and topical imiquimod 5%. A variety of measuring tools are used to monitor response to t …
Childhood morphea is treated with phototherapy, oral or topical calcitriol, topical tacrolimus 0.1%, methotrexate, topical or systemic corti …
Endothelial cell-derived MMP19 promotes pulmonary fibrosis by inducing E(nd)MT and monocyte infiltration.
Zhao W, Wang L, Yang J, Chen X, Guo X, Xu K, Wang N, Zhao W, Xia C, Lian H, Rosas I, Yu G. Zhao W, et al. Cell Commun Signal. 2023 Mar 13;21(1):56. doi: 10.1186/s12964-023-01040-4. Cell Commun Signal. 2023. PMID: 36915092 Free PMC article.
The regulatory mechanism of MMP19 in pulmonary fibrosis was elucidated by blocking its interacting proteins SDF1 and ET1 with AMD3100 and Bosentan, respectively. RESULTS: In this study, we found that MMP19 expression was significantly increased in the lung endothelial cell …
The regulatory mechanism of MMP19 in pulmonary fibrosis was elucidated by blocking its interacting proteins SDF1 and ET1 with AMD3100 and …
Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?
van Thor MCJ, Ten Klooster L, Snijder RJ, Kelder JC, Mager JJ, Post MC. van Thor MCJ, et al. Lung. 2019 Dec;197(6):753-760. doi: 10.1007/s00408-019-00274-9. Epub 2019 Oct 3. Lung. 2019. PMID: 31583452
We report and compare survival, clinical worsening (CW), adverse events, WHO FC, NT-proBNP and 6-min walking test (6MWT) until 2 years after medication initiation. RESULTS: In total, 112 patients receiving bosentan or macitentan (58% female, mean age 62 14 years, 68% WHO F …
We report and compare survival, clinical worsening (CW), adverse events, WHO FC, NT-proBNP and 6-min walking test (6MWT) until 2 years after …
[Pulmonary arterial hypertension].
Montani D, Jaïs X, Sitbon O, Capron F, Simonneau G, Humbert M. Montani D, et al. Rev Mal Respir. 2005 Sep;22(4):651-66. doi: 10.1016/s0761-8425(05)85616-5. Rev Mal Respir. 2005. PMID: 16294183 Review. French.
In less severe cases, the first-line treatment may include bosentan or a prostacyclin analogue. PERSPECTIVES AND CONCLUSIONS: Recent advances in the management of PAH have markedly improved prognosis. ...
In less severe cases, the first-line treatment may include bosentan or a prostacyclin analogue. PERSPECTIVES AND CONCLUSIONS: Recent …
Systemic pharmacological treatment of digital ulcers in systemic sclerosis: a systematic literature review.
Ross L, Maltez N, Hughes M, Schoones JW, Baron M, Chung L, Giuggioli D, Moinzadeh P, Suliman YA, Campochiaro C, Allanore Y, Denton CP, Distler O, Frech T, Furst DE, Khanna D, Krieg T, Kuwana M, Matucci-Cerinic M, Pope J, Alunno A. Ross L, et al. Rheumatology (Oxford). 2023 Dec 1;62(12):3785-3800. doi: 10.1093/rheumatology/kead289. Rheumatology (Oxford). 2023. PMID: 37335850 Free PMC article.
Data from 18 RCTs of 1927 patients and 29 OBSs of 661 patients, at various RoB (total 2588 patients) showed that i.v. iloprost, phosphodiesterase-5 inhibitors and atorvastatin are effective for the treatment of active DUs. Bosentan reduced the rate of future DUs in two RCT …
Data from 18 RCTs of 1927 patients and 29 OBSs of 661 patients, at various RoB (total 2588 patients) showed that i.v. iloprost, phosphodiest …
Definition and Management of Segmental Pulmonary Hypertension.
Dimopoulos K, Diller GP, Opotowsky AR, D'Alto M, Gu H, Giannakoulas G, Budts W, Broberg CS, Veldtman G, Swan L, Beghetti M, Gatzoulis MA. Dimopoulos K, et al. J Am Heart Assoc. 2018 Jul 4;7(14):e008587. doi: 10.1161/JAHA.118.008587. J Am Heart Assoc. 2018. PMID: 29973393 Free PMC article. No abstract available.
Endothelin receptor antagonists for persistent pulmonary hypertension in term and late preterm infants.
More K, Athalye-Jape GK, Rao SC, Patole SK. More K, et al. Cochrane Database Syst Rev. 2016 Aug 18;2016(8):CD010531. doi: 10.1002/14651858.CD010531.pub2. Cochrane Database Syst Rev. 2016. PMID: 27535894 Free PMC article. Review.
Twenty-one infants were randomised to receive either 'iNO plus Bosentan' or 'iNO plus placebo'.In the first study, there was no significant difference in the incidence of death before hospital discharge between the Bosentan and placebo groups (1/23 vs 3/14; RR 0.20, …
Twenty-one infants were randomised to receive either 'iNO plus Bosentan' or 'iNO plus placebo'.In the first study, there was no signi …
2,812 results